TabsDetailsBasic DetailsDate: Monday, November 6, 2017Type: PublicationMedical Product: extended-release (ER) niacin, fenofibrateHealth Outcome(s): gastrointestinal (GI) bleedintracranial hemorrhageDescription: The authors of this report compared rates of major gastrointestinal bleeding and intracranial hemorrhage among initiators of extended-release niacin and initiators of fenofibrate. Read More Materials: Pharmacoepidemiology & Drug Safety 2017;1-8. DOI:10.1002/pds.4343Additional InformationInformationTime Period: January 1, 2007 - August 31, 2013Data Source(s): Mini-Sentinel Distributed Database (MSDD)Related Assessment(s): Niacin and Niacin Combination Products, Fenofibrates, and Omega-3 ProductsConcomitant Use of Niacin and Statins and Concomitant Use of Fenofibrates and StatinsNiacin and Fenofibrate Use and Outcomes with Propensity Score MatchingContributorsAuthor(s): Joshua J. Gagne PharmD, ScD; Monika Houstoun PharmD; Marsha E. Reichman PhD; Christian Hampp PhD; James H. Marshall MPH; Sengwee Toh ScDCorresponding Author: J. J. Gagne, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA. Email: jgagne@bwh.harvard.edu
